Targeting PARP for Chemoradiosensitization: Opportunities, Challenges, and the Road Ahead
AffiliationMassachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
MetadataShow full item record
AbstractIn many patients with cancer, the dose of radiation therapy (RT) that can be safely administered is insufficient to achieve high rates of local tumor control and cure. In others, damage to normal tissues is a concern even at moderate doses. In these settings, RT, or chemoradiation therapy (CRT), ideally would be combined with novel targeted drugs that can enhance the tumoricidal effects of standard therapy but without significantly increased normal tissue toxicity. Over the past decade, major advances in precision medicine have supplied the field of radiation oncology with countless opportunities to enhance the antitumor effects of CRT. However, a large body of preclinical research and clinical investigations on molecular targeted drugs has not yet translated into any meaningful number of combinations of RT or CRT with targeted radiosensitizers that are approved by the US Food and Drug Administration. In fact, to date the epidermal growth factors receptor-directed monoclonal antibody cetuximab remains the only targeted agent approved by the Food and Drug Administration for concurrent administration with RT in head and neck (H&N) cancers. There are considerable challenges to clinical translation of combining targeted drugs with CRT or RT that the field has only recently begun to fully appreciate.
CitationWillers H, Krause M, Faivre-Finn C, Chalmers AJ. Targeting PARP for Chemoradiosensitization: Opportunities, Challenges, and the Road Ahead. Int J Radiat Oncol Biol Phys. 2022;112(2):265-70.
JournalInt J Radiat Oncol Biol Phys
- Poly(ADP-ribose) polymerase inhibition: past, present and future.
- Authors: Curtin NJ, Szabo C
- Issue date: 2020 Oct
- Poly (ADP-ribose) polymerase: An Overview of Mechanistic Approaches and Therapeutic Opportunities in the Management of Stroke.
- Authors: Tiwari P, Khan H, Singh TG, Grewal AK
- Issue date: 2022 Jul
- Therapeutic Targeting of Poly(ADP-Ribose) Polymerase-1 (PARP1) in Cancer: Current Developments, Therapeutic Strategies, and Future Opportunities.
- Authors: Rajawat J, Shukla N, Mishra DP
- Issue date: 2017 Nov
- Clinical Application of Poly(ADP-Ribose) Polymerase Inhibitors in High-Grade Serous Ovarian Cancer.
- Authors: Parkes EE, Kennedy RD
- Issue date: 2016 May
- Poly(ADP-ribose) Polymerase (PARP) and PARP Inhibitors: Mechanisms of Action and Role in Cardiovascular Disorders.
- Authors: Henning RJ, Bourgeois M, Harbison RD
- Issue date: 2018 Dec